Drug
Relacorilant
Relacorilant: highest development phase Phase 3, developed by Corcept Therapeutics. 8 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Corcept Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Relacorilant 150 mg NCT05257408 | Phase 3 | Ovarian Neoplasm |
| Relacorilant NCT04308590 | Phase 3 | Hypercortisolism |
| Relacorilant NCT03697109 | Phase 3 | Cushing Syndrome |
| relacorilant NCT03604198 | Phase 2 | Cushing Syndrome |
| Relacorilant NCT03776812 | Phase 2 | Recurrent Ovarian Cancer |
| Relacorilant NCT07259317 | Phase 2 | Adenocarcinoma |
| Relacorilant 350mg NCT03512548 | Phase 1 | Healthy |
| Relacorilant (3x100 mg softgel capsules) NCT03540836 | Phase 1 | Healthy |
Latest
No recent events.
Follow Relacorilant on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.